Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study

K B Madsen; C Askov-Hansen; R M Naimi; C F Brandt; B Hartmann; Jens Juul Holst; P B Mortensen; P B Jeppesen

doi:10.1016/j.regpep.2013.03.025

Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study

K B Madsen, C Askov-Hansen, R M Naimi, C F Brandt, B Hartmann, Jens Juul Holst, P B Mortensen, P B Jeppesen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

73 Citationer (Scopus)

Abstract

The ileocolonic brake is impaired in short bowel syndrome (SBS) patients with distal bowel resections. An attenuated meal-stimulated hormone secretion may cause gastric hypersecretion, rapid gastric and intestinal transit and a poor adaptation. Attempting to restore this ileocolonic brake, this study evaluated the acute effects of continuous intravenous administration of glucagon-like peptide (GLP) 1 and 2, alone or in combination, on gastrointestinal function in SBS patients.

Originalsprog	Engelsk
Tidsskrift	Regulatory Peptides
Vol/bind	184
Udgave nummer	10
Sider (fra-til)	30-9
Antal sider	10
ISSN	0167-0115
DOI	https://doi.org/10.1016/j.regpep.2013.03.025
Status	Udgivet - 10 jun. 2013

Adgang til dokumentet

10.1016/j.regpep.2013.03.025

Citationsformater

Madsen, K. B., Askov-Hansen, C., Naimi, R. M., Brandt, C. F., Hartmann, B., Holst, J. J., Mortensen, P. B., & Jeppesen, P. B. (2013). Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. Regulatory Peptides, 184(10), 30-9. https://doi.org/10.1016/j.regpep.2013.03.025

Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. / Madsen, K B; Askov-Hansen, C; Naimi, R M; Brandt, C F; Hartmann, B ; Holst, Jens Juul; Mortensen, P B; Jeppesen, P B.

I: Regulatory Peptides, Bind 184, Nr. 10, 10.06.2013, s. 30-9.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Madsen, KB, Askov-Hansen, C, Naimi, RM, Brandt, CF, Hartmann, B , Holst, JJ, Mortensen, PB & Jeppesen, PB 2013, 'Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study', Regulatory Peptides, bind 184, nr. 10, s. 30-9. https://doi.org/10.1016/j.regpep.2013.03.025

Madsen KB, Askov-Hansen C, Naimi RM, Brandt CF, Hartmann B , Holst JJ et al. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. Regulatory Peptides. 2013 jun. 10;184(10):30-9. https://doi.org/10.1016/j.regpep.2013.03.025

Madsen, K B ; Askov-Hansen, C ; Naimi, R M ; Brandt, C F ; Hartmann, B ; Holst, Jens Juul ; Mortensen, P B ; Jeppesen, P B. / Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. I: Regulatory Peptides. 2013 ; Bind 184, Nr. 10. s. 30-9.

@article{db12f6962ab84b8fb42c91a65e764a3e,

title = "Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study",

abstract = "The ileocolonic brake is impaired in short bowel syndrome (SBS) patients with distal bowel resections. An attenuated meal-stimulated hormone secretion may cause gastric hypersecretion, rapid gastric and intestinal transit and a poor adaptation. Attempting to restore this ileocolonic brake, this study evaluated the acute effects of continuous intravenous administration of glucagon-like peptide (GLP) 1 and 2, alone or in combination, on gastrointestinal function in SBS patients.",

author = "Madsen, {K B} and C Askov-Hansen and Naimi, {R M} and Brandt, {C F} and B Hartmann and Holst, {Jens Juul} and Mortensen, {P B} and Jeppesen, {P B}",

year = "2013",

month = jun,

day = "10",

doi = "10.1016/j.regpep.2013.03.025",

language = "English",

volume = "184",

pages = "30--9",

journal = "Regulatory Peptides",

issn = "0167-0115",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study

AU - Madsen, K B

AU - Askov-Hansen, C

AU - Naimi, R M

AU - Brandt, C F

AU - Hartmann, B

AU - Holst, Jens Juul

AU - Mortensen, P B

AU - Jeppesen, P B

PY - 2013/6/10

Y1 - 2013/6/10

N2 - The ileocolonic brake is impaired in short bowel syndrome (SBS) patients with distal bowel resections. An attenuated meal-stimulated hormone secretion may cause gastric hypersecretion, rapid gastric and intestinal transit and a poor adaptation. Attempting to restore this ileocolonic brake, this study evaluated the acute effects of continuous intravenous administration of glucagon-like peptide (GLP) 1 and 2, alone or in combination, on gastrointestinal function in SBS patients.

AB - The ileocolonic brake is impaired in short bowel syndrome (SBS) patients with distal bowel resections. An attenuated meal-stimulated hormone secretion may cause gastric hypersecretion, rapid gastric and intestinal transit and a poor adaptation. Attempting to restore this ileocolonic brake, this study evaluated the acute effects of continuous intravenous administration of glucagon-like peptide (GLP) 1 and 2, alone or in combination, on gastrointestinal function in SBS patients.

U2 - 10.1016/j.regpep.2013.03.025

DO - 10.1016/j.regpep.2013.03.025

M3 - Journal article

C2 - 23511332

VL - 184

SP - 30

EP - 39

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 10

ER -